Should endometrial clear cell carcinoma be classified as type II endometrial carcinoma?

International Journal of Gynecological Pathology

Volumn 34, Issue 1, 2015, Pages 74-84

  Bae, Hyo Sook ^a   Kim, Hyesun ^c   Kwon, Sun Young ^d   Kim, Kyu Rae ^e   Song, Jae Yun ^a   Kim, Insun ^a,b  

^a College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Catholic Kwandong University   (South Korea)

^d Keimyung University   (South Korea)

^e Asan Medical Center   (South Korea)

Author keywords

Clear cell adenocarcinoma; DNA sequencing; Endometrial carcinoma; Endometrioid adenocarcinoma; Immunohistochemistry

Indexed keywords

ASPARTIC PROTEINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; K RAS PROTEIN; MISMATCH REPAIR PROTEIN; NAPSIN A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN ARID1A; PROTEIN P16; PROTEIN P53; PROTEIN PIK3CA; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; DNA SEQUENCE; ENDOMETRIAL CLEAR CELL CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM POLYP; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE SILENCING; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISSENSE MUTATION; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME; VERY ELDERLY; ADENOCARCINOMA, CLEAR CELL; CANCER STAGING; CARCINOGENESIS; CLASSIFICATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; GENETICS; MIDDLE AGED; MUTATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; ONCOGENE RAS; PATHOLOGY; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENES, RAS; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES;

EID: 84918768074     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000111     Document Type: Article

References (54)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997;81:228-32.
4. Boruban MC, Altundag K, Kilic GS, et al. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev 2008; 17:133-8.
5. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39: 46-54.
6. Mariani A, Sebo TJ, Webb MJ, et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev 2003;27:434-41.
7. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998;29:551-8.
8. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecularbased classification. Virchows Arch 2004;444:213-23.
9. Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:84-92.
10. An HJ, Logani S, Isacson C, et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol 2004; 17:530-7.
11. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
12. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
13. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
14. Farrand K, Jovanovic L, Delahunt B, et al. Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. J Mol Diagn 2002;4:150-8.
15. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
16. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91.
17. Zheng W, Xiang L, Fadare O, et al. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011;35:e1-14.
18. Halperin R, Zehavi S, Habler L, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001;22:122-6.
19. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999;18:138-43.
20. Vang R, Whitaker BP, Farhood AI, et al. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001;20:252-9.
21. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
22. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
23. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol 2001;158:1895-8.
24. Peterson LM, Kipp BR, Halling KC, et al. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Int J Gynecol Pathol 2012;31:195-205.
25. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011;224:328-33.
26. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011;35:625-32.
27. Bocker T, Diermann J, Friedl W, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res 1997;57:4739-43.
28. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29:1150-9.
29. Konstantinova D, Kaneva R, Dimitrov R, et al. Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer. DNA Cell Biol 2010;29:65-70.
30. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
31. Demopoulos RI, Mesia AF, Mittal K, et al. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol 1999;18:233-7.
32. Dupont J, Wang X, Marshall DS, et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 2004;94:449-55.
33. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
34. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91:463-9.
35. Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 2011;18:415-37.
36. Goshen R, Chu W, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breastovarian cancer syndrome? Gynecol Oncol 2000;79:477-81.
37. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24:797-806.
38. He M, Breese V, Hang S, et al. BRAF V600E mutations in endometrial adenocarcinoma. Diagn Mol Pathol 2013;22:35-40.
39. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007;38:1074-80.
40. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20-30.
41. Risinger JI, Berchuck A, Kohler MF, et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-3.
42. Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001;91: 22-6.
43. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011;225:189-94.
44. Garcia-Dios DA, Lambrechts D, Coenegrachts L, et al. Highthroughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 2013;128:327-34.
45. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31.
46. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
47. Menard S, Casalini P, Campiglio M, et al. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-78.
48. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
49. Wang LE, Ma H, Hale KS, et al. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 2012;138:377-85.
50. Streeper RS, Svitek CA, Goldman JK, et al. Differential role of hepatocyte nuclear factor-1 in the regulation of glucose-6-phosphatase catalytic subunit gene transcription by cAMP in liver- and kidney-derived cell lines. J Biol Chem 2000;275:12108-18.
51. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
52. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503-12.
53. Chuman Y, Bergman A, Ueno T, et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999;462:129-34.
54. Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005;201:579-86.